Literature DB >> 16377668

Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables.

Jeffrey P Hammel1, Sujata M Bhavnani, Ronald N Jones, Alan Forrest, Paul G Ambrose.   

Abstract

In order to identify patients likely to be infected with resistant bacterial pathogens, analytic methods such as standard regression (SR) may be applied to surveillance data to determine patient- and institution-specific factors predictive of an increased MIC. However, the censored nature of MIC data (e.g., MIC < or = 0.5 mg/liter or MIC > 8 mg/liter) imposes certain limitations on the use of SR. In order to investigate the nature of these limitations, simulations were performed to compare a regression tailored for censored data (censored regression [CR]) and one tailored for an SR. By using a model relating piperacillin-tazobactam MICs against Enterobacter spp. to patient age and hospital bed capacity, 200 simulations of 500 isolates were performed. Various MIC censoring patterns were imposed by using 26 left- or right-censored (L,R) pairs (i.e., MICs < or = 2 mg/liter(L) [2L] or MICs > 2 mg/liter(R) [2R], respectively). Data were fit by CR and SR for which censored MICs were either (i) excluded, (ii) replaced by 2L or 2R, or (iii) replaced by 2(L - 1) or 2(R + 1). Total censoring for the 26 pairs ranged from 7 to 86%. By CR, deviations of average parameter estimates from the true parameter values were <0.10 log2 (mg/liter) for all parameters for each of the 26 pairs. By SR, these deviations were >0.10 log2 (mg/liter) for at least 18 of the 26 pairs for all but one parameter. Two-standard-error confidence intervals for individual parameters contained as little as 0% of cases for all SR approaches but > or = 91.5% of cases for the CR approach. When censored MIC data are modeled, CR may reduce or eliminate biased parameter estimates obtained by SR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16377668      PMCID: PMC1346801          DOI: 10.1128/AAC.50.1.62-67.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Multi-hospital analysis of antimicrobial usage and resistance trends.

Authors:  C A Lesch; G S Itokazu; L H Danziger; R A Weinstein
Journal:  Diagn Microbiol Infect Dis       Date:  2001-11       Impact factor: 2.803

2.  Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

Authors:  Clyde Thornsberry; Daniel F Sahm; Laurie J Kelly; Ian A Critchley; Mark E Jones; Alan T Evangelista; James A Karlowsky
Journal:  Clin Infect Dis       Date:  2002-03-01       Impact factor: 9.079

3.  Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Alan Forrest; Ronald N Jones; Paul G Ambrose
Journal:  Clin Infect Dis       Date:  2003-07-17       Impact factor: 9.079

4.  Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001).

Authors:  Helio S Sader; Douglas J Biedenbach; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2003-09       Impact factor: 2.803

5.  Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.

Authors:  Paul R Rhomberg; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2003-09       Impact factor: 2.803

6.  Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group.

Authors:  C H Ballow; J J Schentag
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

7.  Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals.

Authors:  Sujata M Bhavnani; Wendy A Callen; Alan Forrest; Kristin K Gilliland; David A Collins; Joseph A Paladino; Jerome J Schentag
Journal:  Am J Health Syst Pharm       Date:  2003-10-01       Impact factor: 2.637

8.  Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002).

Authors:  Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2003-10       Impact factor: 2.803

9.  Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci.

Authors:  Scott K Fridkin; Rachel Lawton; Jonathan R Edwards; Fred C Tenover; John E McGowan; Robert P Gaynes
Journal:  Emerg Infect Dis       Date:  2002-07       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.